• Proactive - Interviews for investors

  • By: Proactive
  • Podcast

Proactive - Interviews for investors

By: Proactive
Listen for free

  • Summary

  • Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.
    Show more Show less
Business & Careers Economics Personal Finance Politics & Government
Show more Show less
Episodes
  • GoviEx Uranium unveils low-risk, high-reward Muntanga feasibility study

    GoviEx Uranium unveils low-risk, high-reward Muntanga feasibility study
    Jan 24 2025
    GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical risks. The company plans to produce 2.20 million pounds of uranium annually over a 12-year lifespan. Major emphasised the potential for resource expansion from nearby satellite deposits, which could further enhance the project’s value. Additionally, he outlined the global uranium market dynamics, noting a deficit in supply and growing demand driven by new reactors, life extensions for existing reactors, and advancements in small modular reactors (SMRs). Looking ahead, GoviEx is targeting project construction by 2028 and is actively seeking debt financing and offtake agreements to move forward. Major said, "We’re already sharing our feasibility study with utilities to ensure we meet their requirements." Watch the full interview to learn more about GoviEx’s strategy for meeting global uranium demand. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates! #GoviExUranium #MutangaProject #UraniumMining #ZambiaResources #EnergyDemand #UraniumFeasibility #LowRiskMining #GlobalEnergy #NuclearEnergy #SmallModularReactors
    Show more Show less
    5 mins
  • ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough

    ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough
    Jan 24 2025
    ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer. Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by Professor Nicola Aceto at the Cancer Metastasis Laboratory in Zurich, where they discovered that FDA-approved cardiac drugs could break these clusters into individual cells. In mice and breast cancer patients, this approach showed potential to halt cancer progression. The CEO emphasised Parsortix's central role in identifying patients and monitoring treatment efficacy, predicting global interest and demand for the system. He also discussed ANGLE's broader work with cancer drug developers, including collaborations with companies like AstraZeneca and Eisai, to unlock new approaches to managing cancer. Newland concluded with optimism, envisioning a future where cancer could become a manageable condition, similar to how HIV/AIDS is now controlled. Discover more about this transformative research and ANGLE PLC’s contributions. Like this video, subscribe to Proactive’s channel, and enable notifications for future updates!" #ANGLEPLC #Parsortix #CancerResearch #CancerBreakthrough #Oncology #Metastasis #CirculatingTumorCells #MedicalInnovation #NatureMedicine #CancerAwareness
    Show more Show less
    11 mins
  • Iofina CEO on record iodine production in 2024, growth plans

    Iofina CEO on record iodine production in 2024, growth plans
    Jan 24 2025
    Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output. The company is also making strides with IO#11, set to begin production in Q3 2025, and ongoing discussions for IO#12, signalling further expansion. Becker emphasised strong global iodine demand, with prices climbing above $70 per kilogram, benefiting Iofina's operations. Despite minor shipping delays pushing sales into 2025, Becker assured investors of continued growth and progress. He also celebrated the company's safety track record, with no lost-time accidents since 2021. Stay tuned for more updates on Iofina PLC and its plans for the future. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!" #Iofina #IodineProduction #ChemicalIndustry #BusinessGrowth #RecordProduction #IO10Plant #IO11Plant #GlobalDemand #ChemicalSafety #ProactiveInvestors
    Show more Show less
    6 mins

What listeners say about Proactive - Interviews for investors

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available